Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 14/20 | 0.70 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.52 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | CLK3 | P49761 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16473230 | 0.84 | TGFBR1 (0.54) | TRPA1TGFBR1TRPM8 | |
| SCHEMBL16473229 | 0.84 | TGFBR1 (0.56) | TRPA1TGFBR1TRPM8DYRK3CLK1 | |
| SCHEMBL15639540 | 0.84 | TRPA1 (0.75) | TRPA1TGFBR1TRPM8CDC7DYRK3 | |
| SCHEMBL15639196 | 0.83 | TGFBR1 (0.53) | TRPA1TGFBR1TRPM8DYRK3CLK1 | |
| SCHEMBL15639774 | 0.83 | TRPA1 (0.62) | TRPA1TGFBR1TRPM8CDC7DYRK3 | |
| SCHEMBL16473227 | 0.82 | TRPA1 (0.55) | TRPA1TGFBR1TRPM8 | |
| SCHEMBL16473228 | 0.82 | TRPA1 (0.51) | TRPA1TGFBR1TRPM8CDC7DYRK3 | |
| SCHEMBL15640012 | 0.81 | TGFBR1 (0.71) | TRPA1TGFBR1TRPM8CDC7DYRK3 | |
| SCHEMBL16473226 | 0.81 | TRPA1 (0.54) | TRPA1TGFBR1TRPM8DYRK3CLK1 | |
| SCHEMBL15639442 | 0.79 | TGFBR1 (0.68) | TRPA1TGFBR1TRPM8CDC7DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878992-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | MIDCAP FINANCIAL TRUST | 2017-04-06 | — | — | US | disclosed |
| US-9145433-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107073-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | TRPA1 4474/4885TGFBR1 128/4885TRPM8 1885/4885 |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR1, TGFBR2, ACVR1 | TRPA1 4073/4885TGFBR1 1/4885TRPM8 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.